Month: June 2019

Human Rights Council (2019): Core Group circulates zero draft on access to medicines and vaccines

Posted on by Thiru

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341

At the 41st session (24 June 2019 – 12 July 2019) of the Human Rights Council, a bloc of countries known as the the Core Group (Brazil, China, Egypt, Indonesia, India, Senegal, South Africa and Thailand) have circulated a resolution…

SCP 30: General statement of Knowledge Ecology International

Posted on by Thiru

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341

On Monday, 24 June 2019, Knowledge Ecology International (KEI) delivered this opening statement at WIPO’s 30th Session of the Standing Committee on the Law of Patents (SCP). The Committee elected a new chair, Sarah Whitehead, United Kingdom of Great Britain…

KEI and UACT comments on NIH license to GLG Pharma over a STAT3 Inhibitor “in all proliferative diseases” (and NIH Response)

Posted on by Luis Gil Abinader

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341

(UPDATE: The NIH provided a response to our comments on June 18, 2019) On June 7, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 23798, on the “Prospective Grant of an Exclusive Patent License: The…

UPenn, Nationwide Children’s Hospital refuse to disclose which patents they licensed to Novartis for Zolgensma

Posted on by Laurel Boman

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341

Zolgensma, Novartis’s new $2.1 million gene therapy for children with spinal muscular atrophy (SMA), is a remarkable breakthrough with a steep price tag: the cost per child is $2.125 million. The treatment was developed using research funded by the National…